Synergistic effects of proteasome inhibitor carfilzomib in combination with tyrosine kinase inhibitors in imatinib-sensitive and -resistant chronic myeloid leukemia models

by Crawford, L J, Chan, E T, Aujay, M, Holyoake, T L, Melo, J V, Jorgensen, H G, Suresh, S, Walker, B, Irvine, A E
Published 2014

SOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function

by Hansen, N, Ågerstam, H, Wahlestedt, M, Landberg, N, Askmyr, M, Ehinger, M, Rissler, M, Lilljebjörn, H, Johnels, P, Ishiko, J, Melo, J V, Alexander, W S, Bryder, D, Järås, M, Fioretos, T
Published 2013